Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia

Intensive Care Medicine - Tập 30 Số 5 - Trang 976-979 - 2004
Emmanuel Boselli1, Dominique Breilh2, Maxime Cannesson1, Fabien Xuereb2, Thomas Rimmelé1, D. Chassard1, Marie-Claude Saux2, Bernard Allaouchiche3
1Department of Anesthesiology and Intensive Care, Hôtel-Dieu, Lyon cedex 02, France
2Clinical Pharmacokinetics Laboratory, Haut-Lévêque Hospital, Pessac, France
3Department of Anesthesiology and Intensive Care, Edouard Herriot Hospital, Lyon, France

Tóm tắt

Từ khóa


Tài liệu tham khảo

Perry CM, Markham A (1999) Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57:805–843

Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, Maravi-Poma E, Torres-Marti A, Nava J, Martinez-Pellus A, Palomar M, Barcenilla F (2001) Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 27:493–502

Joshi M, Bernstein J, Solomkin J, Wester BA, Kuye O (1999) Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother 43:389–397

Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT (1989) Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 33:1964–1969

Burgess DS, Waldrep T (2002) Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther 24:1090–1104

Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP (2001) Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam. J Antimicrob Chemother 48:259–267

Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Bérezin E (1994) Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrob Agents Chemother 38:2780–2784

Bergogne-Berézin E (1995) New concepts in the pulmonary disposition of antibiotics. Pulm Pharmacol 8:65–81

Boselli E, Allaouchiche B (2001) Diffusion pulmonaire des antibiotiques. Analyse critique de la littérature. Ann Fr Anesth Réanim 20:612–630

Yamazaki K, Ogura S, Ishizaka A, Oh-hara T, Nishimura M (2003) Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Am J Respir Crit Care Med 168:1304–1307

Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140

Pham LH, Brun-Buisson C, Legrand P, Rauss A, Verra F, Brochard L, Lemaire F (1991) Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am Rev Respir Dis 143:1055–1061

Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B (2003) Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 31:2102–2106

Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867–903

Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963